^
Association details:
| Biomarker: | PPFIBP2-BRAF fusion |
|---|---|
| Cancer: | Melanoma |
| Drug: | Muphoran (fotemustine) (DNA synthesis inhibitor, Alkylating agent) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion
Excerpt:
After four doses of ipilimumab, restaging showed progressive disease in both intra- and extra-cranial sites. A large brain metastasis was resected and an induction regimen of fotemustine was commenced, but by February 2014 the patient had developed progressive microcyticanemia and a CT scan demonstrated three new bowel metastases...At this time, in April2014, a PPFIBP2-BRAFfusion was discovered in DNA extracted from a resected brain metastasis...
DOI:
10.1111/pcmr.12388
